VBL Therapeutics Announces Insider Buying
VBL Therapeutics (Nasdaq: VBLT) announced that its Chairman, Dr. Bennett Shapiro, CEO Prof. Dror Harats, and other board members have purchased approximately 200,000 shares in open-market transactions between November 24 and December 3, 2020. This insider buying may signal confidence in the company's future prospects. VBL focuses on developing first-in-class treatments for cancer and immune/inflammatory conditions, with its leading candidate, VB-111, currently in a Phase 3 trial for platinum-resistant ovarian cancer.
- Insider buying: Chairman and CEO purchased approximately 200,000 shares, signaling confidence in the company's future.
- VBL's lead candidate, VB-111, is in a Phase 3 trial for platinum-resistant ovarian cancer, indicating progress in clinical development.
- None.
TEL AVIV, Israel, Dec. 07, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that the Company's Chairman of the Board, Dr. Bennett Shapiro, the CEO, Prof. Dror Harats and additional Company board members and senior management, made open-market purchases of approximately 200K shares of VBLT, between November 24 and December 3, 2020.
About VBL
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for areas of unmet need in cancer and immune/inflammatory indications. VBL has developed three platform technologies: a gene-therapy based technology for targeting newly formed blood vessels with focus on cancer, an antibody-based technology targeting MOSPD2 for anti-inflammatory and immuno-oncology applications, and the Lecinoxoids, a family of small-molecules for immune-related indications. VBL’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is being developed to treat a wide range of solid tumors. VB-111 is currently being studied in a VBL-sponsored Phase 3 potential registration trial for platinum-resistant ovarian cancer.
INVESTOR CONTACT:
Irina Koffler
LifeSci Advisors, LLC
ikoffler@lifesciadvisors.com
646-970-4681
FAQ
What recent stock purchases were made by VBL Therapeutics executives?
What is the focus of VBL Therapeutics?
What is the status of VBL Therapeutics' lead product candidate?
What does insider buying indicate for VBL Therapeutics?
